Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flurandrenolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | PGR | P06401 | 6/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flurandrenolide SCHEMBL5042122 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1HIF1APGRAR | |
| Flurandrenolide SCHEMBL4694 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1HIF1APGRAR | |
| Flurandrenolide SCHEMBL21111542 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1HIF1APGRAR | |
| Flurandrenolide SCHEMBL13769220 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1HIF1APGRAR | |
| Flurandrenolide SCHEMBL5490827 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1HIF1APGRAR | |
| Flurandrenolide SCHEMBL3692151 | 0.98 | CYP3A4 (0.97) | CYP3A4NR3C1HIF1APGRAR | |
| SCHEMBL10028415 | 0.92 | PGR (0.85) | CYP3A4NR3C1HIF1APGRAR | |
| SCHEMBL11862078 | 0.89 | CYP3A4 (0.80) | CYP3A4NR3C1HIF1APGRAR | |
| SCHEMBL11681436 | 0.88 | CYP3A4 (0.79) | CYP3A4NR3C1HIF1APGRAR | |
| SCHEMBL3655013 | 0.88 | CYP3A4 (0.79) | CYP3A4NR3C1HIF1APGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116507626-A | Compositions and methods for modulating short-chain dehydrogenase activity | 罗迪奥治疗公司 | 2023-07-28 | — | — | CN | claimed |
| US-20230192717-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY | 2023-06-22 | — | — | US | claimed |
| EP-4153299-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | Rodeo Therapeutics Corporation (US) | 2023-03-29 | — | — | EP | claimed |
| US-20230039604-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | RODEO THERAPEUTICS CORPORATION | 2023-02-09 | — | — | US | claimed |
| US-20260125398-A1 | 5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12583934-B2 | Anti-CD26 antibodies and uses thereof | ADIENNE S.A. (CH) | 2026-03-24 | — | — | US | disclosed |
| EP-4709480-A1 | 5,6-FUSED BICYCLIC AMIDES AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | Amgen Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709481-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | Amgen Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709479-A1 | 6,6-FUSED BICYCLIC AMIDES AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | Amgen Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250051470-A1 | METHODS OF TREATING GRAFT VERSUS HOST DISEASE | ADIENNE S.A. (CH) | 2025-02-13 | — | — | US | disclosed |
| US-20240409557-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2024-12-12 | — | — | US | disclosed |
| WO-2024233563-A1 | 6,6-FUSED BICYCLIC AMIDES AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2022238978-A1 | METHODS OF TREATING GRAFT VERSUS HOST DISEASE | ADIENNE S.A. (CH) | 2022-11-17 | — | — | WO | disclosed |
| US-20220202851-A1 | BIODEGRADABLE POLYESTERAMIDE USED FOR THE TREATMENT OF ARTHRITIC DISORDERS | DSM IP ASSETS BV (NL) | 2022-06-30 | — | — | US | disclosed |
| WO-2022023792-A1 | TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES | ADIENNE S.A. (CH) | 2022-02-03 | — | — | WO | disclosed |
| US-20140309398-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS | 2014-10-16 | — | — | US | disclosed |
| US-20140309398-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS | 2014-10-16 | — | — | US | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2009045539-A2 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039604-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | NR3C1 1540/4885CYP3A4 1086/4885HIF1A 874/4885 |
| US-20230192717-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | NR3C1 1540/4885CYP3A4 1086/4885HIF1A 874/4885 |
| US-20220202851-A1 | BIODEGRADABLE POLYESTERAMIDE USED FOR THE TREATMENT OF ARTHRITIC DISORDERS | ACMSD, ALAD, DTD1 | NR3C1 2740/4885CYP3A4 2554/4885HIF1A 802/4885 |
| US-20240409557-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | HPGD, ADH1A, ADH5 | NR3C1 1094/4885CYP3A4 213/4885HIF1A 2250/4885 |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | NR3C1, NR3C2, C3AR1 | NR3C1 1/4885CYP3A4 728/4885HIF1A 4459/4885 |
| US-12583934-B2 | Anti-CD26 antibodies and uses thereof | CD2, IGLV6-57, CD22 | NR3C1 4513/4885CYP3A4 3825/4885HIF1A 1436/4885 |
| US-20140309398-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | SERPINA6, NR3C1, NR3C2 | NR3C1 2/4885CYP3A4 229/4885HIF1A 4721/4885 |
| US-20260125398-A1 | 5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | ADH1A, ADH5, ADH1C | NR3C1 241/4885CYP3A4 335/4885HIF1A 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.